Summary:
Organon LLC., a subsidiary of Organon & Co. / “A Phase 3, Open-label, Multi-center, Single-arm Study to Assess Contraceptive Efficacy and Safety of the Nomegestrol Acetate + 17β-estradiol Combined Oral Contraceptive (OG-8175A) in Premenopausal Females
Qualified Participants Must:
• Must be a Female that is 18-35 years of age.
Qualified Participants May Receive:
Compensation up to $1600 for 7 Visits over a year. Free Birth Control for 52 weeks.